4 results
Primary: To compare the reduction in frequency of partial-onset seizures on each of two trough ranges of everolimus (3-7 ng/mL and 9-15 ng/mL) versus placebo in patients with TSC who are taking one to three AEDs. Key secondary: Ability to completely…
Primary Objective- To evaluate the safety and tolerability of AP30663 in healthy malesSecondary Objectives- To evaluate the pharmacokinetic profile of AP30663.Exploratory Objectives- To evaluate the effect of AP30663 on electrocardiographical…
Primary ObjectivesTo evaluate the safety and tolerability of AP30663 in healthy males at doses up to 12mg/kgExploratory ObjectiveTo evaluate the effect of AP30663 on electrocardiographical parameters.
Primary Objective:* To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) following 20 weeks of treatment with OM or placeboSecondary…